Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Ensign Group is lead sponsor; 0 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-08-25Current report (material event)
- 8-K2026-08-20Current report (material event)
- SCHEDULE 13G/A2026-07-31SCHEDULE 13G/A
- SCHEDULE 13G/A2026-07-28SCHEDULE 13G/A
- 8-K2026-07-27Current report (material event)
- 10-Q2026-07-27Quarterly report
- 8-K2026-06-15Current report (material event)
- 8-K2026-06-10Current report (material event)
- 8-K2026-05-18Current report (material event)
- 8-K2026-04-30Current report (material event)
- 10-Q2026-04-30Quarterly report
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- ARS2026-04-02Annual report to holders
- DEFA14A2026-04-02DEFA14A
- DEF 14A2026-04-02Proxy statement
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-10SCHEDULE 13G/A
- SCHEDULE 13G2026-02-09SCHEDULE 13G
- 8-K2026-02-04Current report (material event)
- 10-K2026-02-04Annual report
- 8-K2025-11-03Current report (material event)
- 10-Q2025-11-03Quarterly report
- 8-K2025-08-26Current report (material event)
- 8-K2025-07-24Current report (material event)
- 10-Q2025-07-24Quarterly report
- S-82025-06-26Employee stock plan
- 8-K2025-06-20Current report (material event)
- 8-K2025-05-20Current report (material event)
- SCHEDULE 13G/A2025-04-30SCHEDULE 13G/A
- 8-K2025-04-29Current report (material event)
- 10-Q2025-04-29Quarterly report
- ARS2025-04-04Annual report to holders
- DEFA14A2025-04-04DEFA14A
- DEF 14A2025-04-04Proxy statement
- 8-K2025-02-05Current report (material event)
- 10-K2025-02-05Annual report
- SC 13G/A2024-11-14Large holder update
- 8-K2024-10-24Current report (material event)
- 10-Q2024-10-24Quarterly report
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.